Focused On-demand Library for Nuclear pore complex protein Nup160

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q12769

UPID:

NU160_HUMAN

Alternative names:

160 kDa nucleoporin; Nucleoporin Nup160

Alternative UPACC:

Q12769; B4DYE8; B4E2J9; Q08AD3; Q7Z5X6; Q96GB3; Q9H660

Background:

Nuclear pore complex protein Nup160, also known as a 160 kDa nucleoporin, plays a crucial role as a component of the nuclear pore complex (NPC). It is pivotal in poly(A)+ RNA transport, facilitating the exchange between the nucleus and the cytoplasm. This protein's involvement in cellular processes underscores its importance in maintaining cellular function and integrity.

Therapeutic significance:

Nup160's association with Nephrotic syndrome 19, a severe renal disease leading to chronic kidney disease, highlights its therapeutic significance. Understanding the role of Nuclear pore complex protein Nup160 could open doors to potential therapeutic strategies for managing and treating this challenging condition.